Examkin

Soru

Zorluk: ZorInfectious Diseases

Match each patient's clinical presentation with the most appropriate initial or definitive targeted pharmacotherapy.

  • A 34-year-old man with a history of renal transplantation presents with fever, pleuritic chest pain, and hemoptysis. Chest CT reveals a dense nodule with a surrounding halo of ground-glass opacity. Serum galactomannan assay is positive.Voriconazole
  • A 52-year-old woman with diabetic ketoacidosis presents with unilateral facial pain, periorbital edema, and a black necrotic eschar on the nasal turbinate. Biopsy shows broad, nonseptate hyphae branching at wide angles.Liposomal amphotericin B and surgical debridement
  • A 41-year-old forestry worker from Wisconsin presents with a chronic cough, low-grade fever, and ulcerated, verrucous skin lesions on his arms. Sputum microscopy reveals large yeast cells with broad-based budding.Itraconazole
  • A 29-year-old man with HIV and a CD4 count of 40 cells/mm³ presents with fever, insidious onset of severe headache, and lethargy. CSF analysis shows elevated opening pressure and a profoundly positive cryptococcal antigen test. He is treatment-naïve.Liposomal amphotericin B and flucytosine

Cevap

Invasive aspergillosis is treated with Voriconazole. Mucormycosis is treated with Liposomal amphotericin B and surgical debridement. Mild-to-moderate Blastomycosis is treated with Itraconazole. Cryptococcal meningitis is treated with Liposomal amphotericin B and flucytosine.
Each fungal pathogen has a distinct targeted therapy based on its intrinsic susceptibilities, the severity of illness, and the site of infection. Invasive aspergillosis requires voriconazole. Mucormycosis requires a combined medical (liposomal amphotericin B) and surgical approach. Mild-to-moderate blastomycosis responds well to itraconazole. Cryptococcal meningitis induction requires a fungicidal regimen of liposomal amphotericin B and flucytosine to rapidly clear the central nervous system.

Adım Adım Çözüm

1
Analyze the first clinical presentation to identify the pathogen and treatment.
The renal transplant patient with hemoptysis, a 'halo sign' on CT, and a positive galactomannan assay has invasive aspergillosis, which is treated with voriconazole.
Voriconazole provides superior survival benefits for invasive Aspergillus infections compared to other systemic antifungals.
2
Evaluate the second vignette for diagnosis and management.
The patient with diabetic ketoacidosis, a nasal eschar, and right-angle branching nonseptate hyphae has mucormycosis. This requires liposomal amphotericin B and urgent surgical debridement.
Medical therapy alone cannot penetrate the necrotic, ischemic tissue characteristic of mucormycosis; surgical removal of the infected tissue is mandatory.
3
Identify the pathogen in the third scenario and its corresponding therapy.
The forestry worker from Wisconsin with chronic cough, verrucous skin lesions, and broad-based budding yeast has mild-to-moderate blastomycosis, correctly treated with oral itraconazole.
Itraconazole is highly effective and the drug of choice for non-life-threatening, non-CNS endemic mycoses.
4
Assess the fourth vignette to determine the appropriate induction therapy.
The HIV patient with advanced immunosuppression, headache, and positive CSF cryptococcal antigen has cryptococcal meningitis. Standard induction therapy is liposomal amphotericin B combined with flucytosine.
This combination rapidly sterilizes the cerebrospinal fluid and significantly reduces mortality during the induction phase (typically the first two weeks).

Anahtar Kavram

Targeted Antifungal Pharmacotherapy for Systemic and Opportunistic Mycoses
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru